Suggested remit: To appraise the clinical and cost effectiveness of upadacitinib within its marketing authorisation for treating giant cell arteritis.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6299

Provisional Schedule

Committee meeting 14 October 2025
Expected publication 25 February 2026

Project Team

Project lead Leena Issa

Email enquiries

External Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick

Stakeholders

Companies sponsors AbbVie
Others Department of Health and Social Care
  NHS England
Patient carer groups PMRGCA UK (Polymyalgia Rheumatica & Giant Cell Arteritis UK)
  Vasculitis UK
Professional groups British Society for Rheumatology
  Royal College of Physicians
Associated public health groups None
Comparator companies Fresenius Kabi (tocilizumab) – confidentiality agreement not signed, not participating
  Roche (tocilizumab) – confidentiality agreement signed, participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health – Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  NHS Wales Joint Commissioning Committee
  Scottish Medicines Consortium
  Welsh Government
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
23 May 2025 The final stakeholder list was updated in May 2025 to include a relevant provisional consultee.
14 March 2025 Invitation to participate
23 January 2025 - 20 February 2025 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6299
23 January 2025 In progress. Scoping commencing
06 December 2024 Please note that following on from a request received from the company, this appraisal has been scheduled back into the work programme. The appraisal is now anticipated to begin in mid-March 2025 when we will write to you about how you can get involved.
13 May 2024 Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course.  In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. 
28 April 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual